{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao SS"],"funding":["Honjo International Scholarship Foundation","Royal Society of Medicine","Pfizer","National Institute of Health","National Institute for Health Research (NIHR)","NIAMS NIH HHS","NIH","Royal College of Physicians"],"pagination":["2025-2030"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7967894"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["58(11)"],"pubmed_abstract":["<h4>Objectives</h4>This study aimed to compare comorbidities and biologic DMARD (bDMARD) use between AS and non-radiographic axial SpA (nr-axSpA) patients, using a large cohort of patients from routine clinical practice in the United States.<h4>Methods</h4>We performed a cross-sectional study using electronic medical records from two academic hospitals in the United States. Data were extracted using automated searches (⩾3 ICD codes combined with text searches) and supplemented with manual chart review. Patients were categorized into AS or nr-axSpA according to classification criteria. Disease features, comorbidities (from a list of 39 chronic conditions) and history of bDMARD prescription were compared using descriptive statistics.<h4>Results</h4>Among 965 patients identified, 775 (80%) were classified as having axSpA. The cohort was predominantly male (74%) with a mean age of 52.5 years (s.d. 16.8). AS patients were significantly older (54 vs 46 years), more frequently male (77% vs 64%) and had higher serum inflammatory markers than those with nr-axSpA (median CRP 3.4 vs 2.2 mg/dl). Half of all patients had at least one comorbidity. The mean number of comorbidities was 1.5 (s.d. 2.2) and similar between AS and nr-axSpA groups. A history of bDMARD-use was seen in 55% of patients with no difference between groups. The most commonly prescribed bDMARDs were adalimumab (31%) and etanercept (29%). Ever-prescriptions of individual bDMARDs were similar between AS and nr-axSpA.<h4>Conclusion</h4>Despite age differences, nr-axSpA patients had similar comorbidity burdens as those with AS. Both groups received comparable bDMARD treatment in this United States clinic-based cohort."],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States."],"pmcid":["PMC7967894"],"funding_grant_id":["ACF-2014-07-005","NIH-P30-AR072577","P30 AR072577","3543","K24 AR055989","NIH-K24AR055989"],"pubmed_authors":["Moots RJ","Zhao SS","Lyu H","Ermann J","Xu C","Tedeschi SK","Liao KP","Solomon DH","Yoshida K","Goodson NJ"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.","description":"<h4>Objectives</h4>This study aimed to compare comorbidities and biologic DMARD (bDMARD) use between AS and non-radiographic axial SpA (nr-axSpA) patients, using a large cohort of patients from routine clinical practice in the United States.<h4>Methods</h4>We performed a cross-sectional study using electronic medical records from two academic hospitals in the United States. Data were extracted using automated searches (⩾3 ICD codes combined with text searches) and supplemented with manual chart review. Patients were categorized into AS or nr-axSpA according to classification criteria. Disease features, comorbidities (from a list of 39 chronic conditions) and history of bDMARD prescription were compared using descriptive statistics.<h4>Results</h4>Among 965 patients identified, 775 (80%) were classified as having axSpA. The cohort was predominantly male (74%) with a mean age of 52.5 years (s.d. 16.8). AS patients were significantly older (54 vs 46 years), more frequently male (77% vs 64%) and had higher serum inflammatory markers than those with nr-axSpA (median CRP 3.4 vs 2.2 mg/dl). Half of all patients had at least one comorbidity. The mean number of comorbidities was 1.5 (s.d. 2.2) and similar between AS and nr-axSpA groups. A history of bDMARD-use was seen in 55% of patients with no difference between groups. The most commonly prescribed bDMARDs were adalimumab (31%) and etanercept (29%). Ever-prescriptions of individual bDMARDs were similar between AS and nr-axSpA.<h4>Conclusion</h4>Despite age differences, nr-axSpA patients had similar comorbidity burdens as those with AS. Both groups received comparable bDMARD treatment in this United States clinic-based cohort.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-20T02:26:42.184Z","creation":"2025-04-20T02:26:42.184Z"},"accession":"S-EPMC7967894","cross_references":{"pubmed":["31081033"],"doi":["10.1093/rheumatology/kez171"]}}